ClinicalTrials.gg
RecruitingNCT06350786ROMUpdated Jun 15, 2026

Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Subacute or Chronic Pain Pain: a Randomized Controlled Trial

An interventional study of P-Dragees blue Lichtenstein, Placebo dragees and Control group (EM) in Chronic Pain and Subacute Pain, sponsored by Cosima Locher. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Cosima Locher · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Chronic Pain with a site in Switzerland — 9 open to participants now, 9 under way, none of them phase 3. Chronic Pain · Switzerland.

Planned enrollment
12th of 22
86 · median 106
Started
2024
with 1 other
No phase
14 of 43
3 open now
Registered
39th of 43
by date

Among the 43 studies in Chronic Pain with a site in Switzerland, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, and was the 39th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

9 of the 43 studies in Chronic Pain with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Chronic Pain with a site in Switzerland, or all of them as a file.
02

Study summary

This study aims to evaluate whether the reduction of the daily morphine equivalent dose (MED) in patients with subacute and chronic pain can be decreased with an open-label placebo (OLP) intervention in comparison to an electronic monitoring (EM) control group. The participants will receive the intervention (OPL or EM) over the duration of six weeks. Diverse psychological and health measures will be assessed with questionnaires over the course of the intervention. Furthermore, evaluation outcomes, qualitative outcomes and safety outcomes will be assessed. It is hypothesized that the OLP-intervention group in comparison to the EM-control group will have a significantly lower consumption of MED over the course of the study. Furthermore, this study aims to evaluate whether the OLP intervention can reduce opioid withdrawal symptoms in comparison to the control group.

Read the detailed description

Pain is a major global health problem and is often treated with opioid medication, although risks outweigh the benefits (EFIC, 2022; Goldberg \& McGee, 2011; Sandhu et al., 2018). The administration of an open-label placebo (OLP) treatment, i.e., the placebo treatment with full disclosure of being a placebo, has proven to be an effective treatment in pain syndromes [i.e., chronic low back pain (Carvalho et al., 2016; Kleine-Borgmann et al., 2019) and irritable bowel syndrome (Kaptchuk et al., 2010)]. Likewise, meta-analyses reveal that patients in an OLP condition exhibit significantly greater improvement in pain relief than those in a control group (Buergler et al., 2023; von Wernsdorff et al., 2021). Moreover, and of relevance when it comes to the need to reduce opioid medication, OLPs have been shown to be a promising candidate for drug tapering: In line with the conditioning paradigm, the drug as the unconditioned stimulus is paired with the neutral stimulus of an OLP in a learning phase. Then, the OLP alone becomes a conditioned stimulus (Benedetti, 2008; Doering \& Rief, 2012; Martin-Pichora et al., 2011; Price et al., 1999).

A new line of research that indicates that OLPs are effective as an adjunctive treatment for the reduction of drugs have been shown to be feasible for the reduction of active medication in opioid use disorder (Belcher et al., 2019, 2023), acute pain (Bernstein et al., 2019; Flowers et al., 2021; Morales-Quezada et al., 2020; Sezer et al., 2021), chronic posttraumatic pain (Estudillo-Guerra et al., 2021), and ADHD (Sandler et al., 2010; Sandler \& Bodfish, 2008).

Despite these promising findings, there is a lack of trials that examine OLP as adjunctive treatment for the reduction of opioid medication in the subacute and chronic pain population. OLPs are suitable for the controlled reduction of long-acting opioids that are embedded in the planned reduction regimen, and could provide a means of harnessing analgesic placebo effects in patients with subacute and chronic pain, without any loss in pain management efficacy. The major goal of our study is therefore to support participants in their aim to reduce their opioid intake.

03

Conditions studied

  • Chronic Pain
  • Subacute Pain

Browse trials for

Keywords

  • Open Label Placebos
  • Chronic Pain
  • Subacute Pain
  • Opioid Reduction
  • Medication Reduction
  • OLP
  • Opioids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • ≥ 18 years of age
  • German speaking
  • Pain lasting ≥ 4 weeks, including subacute pain (4-12 weeks) and chronic pain (>12 weeks)
  • Opioid medication for pain management for ≥ 4 weeks
  • Oral intake of opioid medication
  • Motivation for opioid reduction
  • Participants have a primary treating physician who performs the reduction of the opioid medication
  • Having access to a computer or tablet with an email-account

Exclusion criteria

Exclusion Criteria:

  • Having psychotic symptoms
  • Suicidality
  • Cognitive impairment to everyday life
  • Planned surgery within the next two months that is expected to affect opioid intake
  • Known illegal drug or harmful alcohol consumption
  • Intolerance of the ingredients of the placebo pill (e.g., lactose, sucrose, corn-starch)
  • Serious health problems that make study participation impossible
  • Simultaneous participation in other studies with drugs or pain specific interventions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Open-Label Placebo

    The intervention involves administering "P-Dragees blue Lichtenstein," blue placebo pills devoid of active ingredients. Each pill contains lactose monohydrate; magnesium stearate; microcrystalline cellulose; sucrose; glucose syrup; corn-starch; highly dispersed silicon dioxide; white clay; macrogol glycerol hydroxy stearate; Gum arabic; montanglycol wax; povidone; talcum; titanium dioxide; calcium carbonate; macrogol 6000; patent blue V; aluminium salt. Participants receive an evidence-based rationale, explaining why the placebo treatment is deemed effective for pain. They are informed that the pills are placebos and are instructed to pair them with opioid medication for 7 days. After 7 days until the end of the study they are instructed to continue to pair their opioid medication with an OLP pill and take additionally placebo pills on the basis of their need. During the intervention, participants use electronic monitoring (EM) to track medication and OLP intakes.

    Other: P-Dragees blue Lichtenstein, Placebo dragees

  • Other
    Electronic monitoring (EM) control group

    EM is a method to objectively measure adherence and serves as the primary intervention component on the basis of which adherence trajectories will be discussed. The participants in the EM control group will receive an evidence-based rational designed to foster positive expectations and will be instructed on the mechanisms of EM. The EM control group is structurally equivalent to the OLP group referring to the number and duration of contacts between participants and the study team members as well as to the format of the intervention and the quality of the interaction.

    Other: Control group (EM)

Interventions

  • OtherP-Dragees blue Lichtenstein, Placebo dragees

    In the intervention group, open-label placebos are administered within the framework of a mind-body management intervention approach, which in turn is consistent with the biopsychosocial model of pain and with a patient-centred approach. The verbal interaction follows the four discussion points: 1. Opioids work by telling the body that participants are not experiencing as much pain; 2. Placebos should be taken every time an opioid is taken which supports the reduction of opioid medication (shown by previous studies); 3. By pairing the pills together the brain will learn to release chemicals like endorphins that cause pain-relief in response to the placebo, just as it does in response to the opioid; 4. At a certain point, placebos might provide adequate pain relief, and the participants might need less opioids. In addition, during the intervention, participants use electronic monitoring (EM) to track medication and OLP intakes.

  • OtherControl group (EM)

    In the EM control group, the focus lies on the electronic monitoring of the opioid intake. The treatment rationale is designed to facilitate the reduction of opioid medication by promoting a positive attitude towards the implementation of the reduction. The verbal interaction follows the four discussion points: 1. The collection of EM data allows for greater patients' sense of agency over medication treatment; 2. Tracking of opioid medication use supports the reduction of opioid medication (shown by previous studies); 3. The EM is a useful tool, and daily recording of opioid medication intake should be done; 4. At a certain point, EM might provide adequate pain relief, and participants might need less opioids.

06

What researchers measure

Primary outcomes

  1. Daily opioid consumption (MED):

    Cumulative dose (i.e. total amount) of opioid pain medication consumption based on daily morphine equivalent doses (MED). Data is collected in SEMA3 app.

    Time frame: Daily measure: starts on day 1 after the first intervention visit (baseline, day 0) after randomization and ends on day 42 at the end of the study.

Secondary outcomes

  1. Subjective opioid withdrawal symptoms

    Subjective opioid withdrawal will be assessed with the Subjective Opiate Withdrawal Scale (SOWS). The intensity of the withdrawal symptoms is rated by the patient on a scale between 0 (= not at all) and 4 (= extremely), the scores for individual symptoms are added to a total sum score, which can range from 0 to 64. The secondary endpoint will be the subjective opioid withdrawal score at study end (t3).

    Time frame: Measured three times: on day 0 at the first intervention visit (baseline), on day 7, and on day 42 at the end of the study.

  2. Pain severity

    Pain severity is assessed using the ICD-11 specifiers or 'extension codes'. The index combines patient-assessed ratings of pain intensity, pain-related distress and pain-related interference. Each of these ratings is assessed on an 11-point NRS rating scale, and these are mapped into the following categories depending on the NRS score: none = NRS 0, mild = NRS 1 - 3, moderate = NRS 4 - 6 and severe = NRS 7 - 10.

    Time frame: Measured three times: on day 0 at the first intervention visit (baseline), on day 7, and at the end of the study on day 42.

  3. Pain disability

    Pain disability is assessed using the pain disability index (PDI) to determine the subjective degree of self-reported impairment caused by the pain problem in everyday life. Seven domains of life are assessed: (1) family and domestic responsibilities, (2) recreation, (3) social activities, (4) occupation, (5) sexual life, (6) self-care and (7) essential activities. The scale ranges from 0 "no impairment" (minimum) - 10 "full impairment" (maximum).

    Time frame: Measured three times: on day 0 at the first intervention visit (baseline), on day 7, and at the end of the study on day 42.

  4. Anxiety

    Anxiety is assessed using the German version of the GAD-7. It is a brief instrument for assessing self-reported generalized anxiety disorder (GAD) symptoms with seven items asking about the main diagnostic criteria of GAD according to the DSM-IV and the ICD-10 criteria. The questions refer to the past two weeks. The scale ranges from "not at all" (minimum); "On some days"; "On more than half of the days"; "almost every day" (maximum).

    Time frame: Measured three times: on day 0 at the first intervention visit (baseline), on day 7, and at the end of the study on day 42.

  5. Depression

    Depression is assessed using Patient Health Questionnaire (PHQ-D) consisting of nine items referring to the past two weeks. The German version of the PHQ was derived from the 'Prime MD Patient Health Questionnaire' and is based on the criteria of the DSM-IV. The scale ranges from "not at all" (minimum); "On some days"; "On more than half of the days"; "almost every day" (maximum).

    Time frame: Measured three times: on day 0 at the first intervention visit (baseline), on day 7, and at the end of the study on day 42.

  6. Pain Opioid Analgesics Beliefs Scale - Cancer

    The POABS-CA in the German version measures pain opioid beliefs based on two components with 10 items and a 5-point Likert scale ranging from 0 ("strongly disagree") to 4 ("strongly agree"). The higher the score, the more negative was the opinion about the use of opioid analgesics for cancer pain, and the stronger was the belief that pain should be endured.

    Time frame: Measured three times: on day 0 at the first intervention visit (baseline), on day 7, and at the end of the study on day 42.

  7. Treatment Expectancy 1

    Expectation measures will be measured in analogy to the most relevant outcomes. First, subjectively expected amount (dose) of opioid medication taken will be examined. For this, the following item will be used at the end of the study "How much opioid medication do you think you will be taking at the end of the study?" The item is answered by naming the type of medication, frequency and amount (dose) of medication.

    Time frame: One-time assessment: measured on day 0 at the first intervention visit (baseline).

  8. Treatment Expectancy 2

    Expectation measures will be measured in analogy to the most relevant outcomes. Second, to measure the expected withdrawal symptoms at the end of the study, items from the SOWS questionnaire will be used, which are expanded with instructions regarding the expectation.

    Time frame: One-time assessment: measured on day 0 at the first intervention visit (baseline).

  9. Placebo pill count

    The intake of placebo pills by the OLP-group will be electronically monitored using survey provided by the app SEMA3. For statistical analysis a ratio will be calculated. A value of the ration close to 1 indicated a more accurate data entry of the placebo pill intake.

    Time frame: Daily measure: starts 1 day after the first intervention visit (baseline, day 0) after randomization and ends on day 42 at the end of the study.

  10. Opioid adherence

    Opioid adherence trajectories will be measured with the app SEMA3 in both groups. In the EM control group, a print of the actual data report from the app (i.e. graph reflecting the pattern of opioid medication intake) will be the basis for the EM-Feedback.

    Time frame: Daily measure: starts 1 day after the first intervention visit (baseline, day 0) after randomization and ends on day 42 at the end of the study.

Other outcomes

  1. Rationale credibility

    The rationale credibility of the OLP intervention will be assessed in the OLP group at study end. The following questions will be assessed: "How credible did you find the explanation of why placebo treatment can work?", "During the study, did you believe that these were placebo tablets that did not contain a pharmacologic agent?", "Did you find the explanation of why the placebo intervention may work helpful?", "How helpful did you find the explanation of why placebo treatment can work?". Answers will be rated on a Likert scale ranging from 0 = Not at all to 4 = Extremely.

    Time frame: One-time assessment: measured on day 42 at the end of the study.

  2. Placebo understanding

    The understanding of placebo will be assessed in both study groups (OLP and control group) at study end using a questionnaire which assesses responders' attitudes regarding non-specific therapies. The first three items of this questionnaire specifically assess the placebo understanding and will be used for this study. The scales differ for the different items. Scale question 1: "I have never heard of the term"; "I have heard the term before, but I do not know"; "A placebo is ... (open question)" Scale question 2: "For me the term is rather positive" "For me the term is neutral, neither positive nor negative"; "For me the term is rather negative"; "I do not know" Scale question 3. "Yes, very often"; "Yes, but rarely"; "No"; "I do not know" Additionally participants are asked, if their understanding of placebos might have changed across the study. Scale: "Yes, to the positive because ... (open question)"; Yes, to the negative because ... (open question)"; "No"; "I do not know"

    Time frame: One-time assessment: measured on day 42 at the end of the study.

  3. Patient Provider Connection

    The Patient Provider Connection is a subscale of the German version of the Healing Encounters and Attitudes List (HEAL) which can be used independently from the six subscales. The seven items are rated on a five-point Likert scale ranging from "not at all" to "very strong" assessing participants' attitudes towards patient-provider connection as a non-specific treatment effect. The scale ranges from 0 "not at all" (minimum) to "very much" 4 (maximum)

    Time frame: One-time assessment: measured on day 42 at the end of the study.

  4. Medication history

    Participants' non-opioid medication intake will be assessed by asking the participants about the medication's name, dosage, and reason for intake. Participants will also be asked about the date of prescription.

    Time frame: Measured two times: on day 0 at the first intervention visit (baseline) and on day 42 at the end of the study.

  5. Primary treating physicians' acceptability of the OLP approach:

    Before the start of the study the primary treating physicians will be asked about their acceptability of the OLP approach from patient and physicians point of view. All items will be rated on a five- or seven-point Likert scale.

    Time frame: One-time assessment, measured before study start: on day -14, prior to the first intervention visit (baseline, day 0).

  6. Primary treating physicians' treatment expectancies

    The primary treating physicians will be given the same questionnaire on treatment expectations as the participants. They will be asked about their subjective expectation of their patients' use of opioid medication and their subjective expectation of their patients' withdrawal symptoms at the end of the study. In addition, the primary treating physicians will be asked to assess their patients' motivation to reduce opioid pain medication. Motivation will be assessed with the following questions on a satisfaction ruler ranging from 0 % to 100 %: 1. "How satisfied is your patient currently with his opioid medication?", 2. "How confident are you that your patient can change her/his use of opioid medication?".

    Time frame: One-time assessment, measured before study start: on day -14, prior to the first intervention visit (baseline, day 0).

  7. Qualitative Outcomes

    The qualitive outcomes will be assessed with an audio recorded semi-structured interviews and will consist of general questions about placebos and core question about the experience of the OLP intervention, acceptability of the OLP approach and prerequisites, ideas and concerns regarding practical OLP implementation.

    Time frame: One-time assessment: measured at the end of the study on day 42.

  8. Additional Symptoms

    Participants answer three questions regarding additional symptoms that might have occurred since the last visit at the study site. The questions are the following: * "How have you been since the last visit?" (open answer format) * "Did you have certain symptoms?" (yes/no) * If the participant answered yes in question 2, a follow up question will be displayed: "Please describe the symptoms you had in detail." (open answer format)

    Time frame: Measured two times: on day 7 after the first intervention visit (baseline) and on day 42.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • EFIC. (2022, May 12). What is the definition of pain? European Pain Federation. https://europeanpainfederation.eu/history/what-is-pain/
  • Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 4;71(3):1-95. doi: 10.15585/mmwr.rr7103a1. PubMed 36327391 ↗
  • Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, Kong LR, Kurita GP, LeBlanc TW, Mercadante S, Novick KLM, Sedhom R, Seigel C, Stimmel J, Bruera E. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023 Feb 1;41(4):914-930. doi: 10.1200/JCO.22.02198. Epub 2022 Dec 5. PubMed 36469839 ↗
  • Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Dev. 2008 Jan;34(1):104-10. doi: 10.1111/j.1365-2214.2007.00797.x. PubMed 18171451 ↗
  • Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010 Jun;31(5):369-75. doi: 10.1097/DBP.0b013e3181e121ed. PubMed 20495473 ↗
  • Bernstein MH, Magill M, Weiss AP, Kaptchuk TJ, Blease C, Kirsch I, Rich JD, Becker SJ, Mach S, Beaudoin FL. Are Conditioned Open Placebos Feasible as an Adjunctive Treatment to Opioids? Results from a Single-Group Dose-Extender Pilot Study with Acute Pain Patients. Psychother Psychosom. 2019;88(6):380-382. doi: 10.1159/000503038. Epub 2019 Sep 27. No abstract available. PubMed 31563914 ↗
  • Belcher AM, Cole TO, Greenblatt AD, Hoag SW, Epstein DH, Wagner M, Billing AS, Massey E, Hamilton KR, Kozak ZK, Welsh CJ, Weintraub E, Wickwire EM, Wish ED, Kaptchuk TJ, Colloca L. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment. BMJ Open. 2019 Jun 21;9(6):e026604. doi: 10.1136/bmjopen-2018-026604. PubMed 31230007 ↗
  • Belcher AM, Cole TO, Massey E, Billing AS, Wagner M, Wooten W, Epstein DH, Hoag SW, Wickwire EM, Greenblatt AD, Colloca L, Rotrosen J, Magder L, Weintraub E, Wish ED, Kaptchuk TJ. Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e237099. doi: 10.1001/jamanetworkopen.2023.7099. PubMed 37043203 ↗
  • Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain. 1999 Nov;83(2):147-56. doi: 10.1016/s0304-3959(99)00081-0. PubMed 10534585 ↗
  • Martin-Pichora AL, Mankovsky-Arnold TD, Katz J. Implicit versus explicit associative learning and experimentally induced placebo hypoalgesia. J Pain Res. 2011 Mar 15;4:67-77. doi: 10.2147/JPR.S15966. PubMed 21559352 ↗
  • Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci. 2012 Mar;33(3):165-72. doi: 10.1016/j.tips.2011.12.001. Epub 2012 Jan 25. PubMed 22284159 ↗
  • Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol. 2008;48:33-60. doi: 10.1146/annurev.pharmtox.48.113006.094711. PubMed 17666008 ↗
  • von Wernsdorff M, Loef M, Tuschen-Caffier B, Schmidt S. Effects of open-label placebos in clinical trials: a systematic review and meta-analysis. Sci Rep. 2021 Feb 16;11(1):3855. doi: 10.1038/s41598-021-83148-6. PubMed 33594150 ↗
  • Buergler S, Sezer D, Gaab J, Locher C. The roles of expectation, comparator, administration route, and population in open-label placebo effects: a network meta-analysis. Sci Rep. 2023 Jul 22;13(1):11827. doi: 10.1038/s41598-023-39123-4. PubMed 37481686 ↗
  • Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010 Dec 22;5(12):e15591. doi: 10.1371/journal.pone.0015591. PubMed 21203519 ↗
  • Kleine-Borgmann J, Schmidt K, Hellmann A, Bingel U. Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial. Pain. 2019 Dec;160(12):2891-2897. doi: 10.1097/j.pain.0000000000001683. PubMed 31479068 ↗
  • Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011 Oct 6;11:770. doi: 10.1186/1471-2458-11-770. PubMed 21978149 ↗
  • Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016 Dec;157(12):2766-2772. doi: 10.1097/j.pain.0000000000000700. PubMed 27755279 ↗
  • Sandhu H, Underwood M, Furlan AD, Noyes J, Eldabe S. What interventions are effective to taper opioids in patients with chronic pain? BMJ. 2018 Sep 27;362:k2990. doi: 10.1136/bmj.k2990. No abstract available. PubMed 30262590 ↗
  • Estudillo-Guerra MA, Mesia-Toledo I, Schneider JC, Morales-Quezada L. The Use of Conditioning Open-Label Placebo in Opioid Dose Reduction: A Case Report and Literature Review. Front Pain Res (Lausanne). 2021 Jul 12;2:697475. doi: 10.3389/fpain.2021.697475. eCollection 2021. PubMed 35295534 ↗
  • Flowers KM, Patton ME, Hruschak VJ, Fields KG, Schwartz E, Zeballos J, Kang JD, Edwards RR, Kaptchuk TJ, Schreiber KL. Conditioned open-label placebo for opioid reduction after spine surgery: a randomized controlled trial. Pain. 2021 Jun 1;162(6):1828-1839. doi: 10.1097/j.pain.0000000000002185. PubMed 33449503 ↗
  • Morales-Quezada L, Mesia-Toledo I, Estudillo-Guerra A, O'Connor KC, Schneider JC, Sohn DJ, Crandell DM, Kaptchuk T, Zafonte R. Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control. Pain Rep. 2020 Jul 20;5(4):e828. doi: 10.1097/PR9.0000000000000828. eCollection 2020 Jul-Aug. PubMed 32766465 ↗
  • Sezer D, de Leeuw M, Netzer C, Dieterle M, Meyer A, Buergler S, Locher C, Ruppen W, Gaab J, Schneider T. Open-Label Placebo Treatment for Acute Postoperative Pain (OLP-POP Study): Study Protocol of a Randomized Controlled Trial. Front Med (Lausanne). 2021 Nov 5;8:687398. doi: 10.3389/fmed.2021.687398. eCollection 2021. PubMed 34805194 ↗
  • Carratta K, Bodonyi K, Frey Nascimento A, Friis D, von Kanel R, Bircher L, Koechlin H, Bernstein M, Streitberger K, Arnet I, Roth AJ, Ronel J, Olliges E, Locher C. Conditioned open-label placebos to facilitate opioid reduction in patients with chronic non-cancer pain: study protocol of a randomised controlled trial. BMJ Open. 2025 May 24;15(5):e098253. doi: 10.1136/bmjopen-2024-098253. PubMed 40413049 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (data set and data dictionary)

Supporting information: Study protocol

Time frame: Beginning 6 months after publication

Access criteria: Researchers with a methodologically sound proposal

Data sharing details ↗ · osf.io

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2026, 27 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 27 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Apr 5, 2024
StartActual
Jun 12, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350786
Lead sponsor
Cosima Locher
Collaborators
Brown University, University of Basel
Responsible party
Cosima Locher (Principal Investigator, University of Zurich) — Sponsor-investigator
First posted
Apr 5, 2024
Start date
Jun 12, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jun 15, 2026

Study contacts

Cosima Locher, PhD
Contact
Cosima.Locher@usz.ch
+41 44 255 12 03
Kiara Bodonyi, MSc
Contact
Kiara.Bodonyi@usz.ch
+41 44 255 14 24
Cosima Locher, PhD
principal investigator · USZ

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion